Compounds > bromodeoxyuridine
Page last updated: 2024-08-17

bromodeoxyuridine and oxyntomodulin

bromodeoxyuridine has been researched along with oxyntomodulin in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hayashi, H; Nakanishi, I; Ooi, A1
Abraham, P; Ashley, SW; Edelman, ER; Jacobs, DO; Kormi, N; Seifert, P; Shen, R; Tavakkolizadeh, A; Whang, EE; Zinner, MJ1
M'Rabet, L; van Beek, NM; van den Berg, JJ; van't Land, B1
Demchyshyn, L; Hartmann, B; Holst, JJ; Martin, GR; Sigalet, DL; Toney, K; Wallace, LE1

Other Studies

4 other study(ies) available for bromodeoxyuridine and oxyntomodulin

ArticleYear
Biological and clinicopathological significance of endocrine differentiation of gastric adenocarcinoma evaluated by double immunohistochemical labeling for chromogranin A and bromodeoxyuridine.
    Japanese journal of clinical oncology, 1990, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Bromodeoxyuridine; Cell Differentiation; Cell Division; Chromogranin A; Chromogranins; Gastrins; Glicentin; Glucagon; Glucagon-Like Peptides; Glycoprotein Hormones, alpha Subunit; Hormones; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Peptide Fragments; Protein Precursors; Serotonin; Somatostatin; Stomach Neoplasms

1990
Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis.
    The Journal of surgical research, 2000, Jun-01, Volume: 91, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Bromodeoxyuridine; Enteritis; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Intestinal Mucosa; Jejunum; Male; Morbidity; Peptides; Rats; Rats, Sprague-Dawley

2000
Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation.
    Digestive diseases and sciences, 2004, Volume: 49, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Bromodeoxyuridine; Caco-2 Cells; Cell Division; Cells, Cultured; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Intestinal Mucosa; Lactoferrin; Methotrexate; Peptides; Polymerase Chain Reaction; Rats; Rats, Inbred Strains

2004
Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.
    American journal of physiology. Gastrointestinal and liver physiology, 2005, Volume: 288, Issue:3

    Topics: Adaptation, Physiological; Animals; Antimetabolites; Body Weight; Bromodeoxyuridine; Cell Proliferation; Dietary Fats; Dietary Proteins; Enzyme-Linked Immunosorbent Assay; Food; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Peptides; Rats; Rats, Sprague-Dawley; Short Bowel Syndrome

2005